Heini Ilves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heini Ilves has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Brian H. Johnston
SomaGenics, Inc., Santa Cruz, California, USA
3 shared publications - Pradheep Chhalliyil
Health Research Institute, 505 Dimick Drive, P.O. Box 370, Fairfield, IA 52556, USA
2 shared publications - Sergei A. Kazakov
Somagenics, Inc., 2161 Delaware Ave, Suite E, Santa Cruz, CA 95060, USA
2 shared publications - Stephanie J. Howard
The Sustainability Council of New Zealand, P.O. Box 24304, Wellington 6142, New Zealand
2 shared publications Adam G. Berger
Harvard-MIT Division of Health Sciences and Technology, Department of Chemical Engineering, Institute for Soldier Nanotechnologies, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
1 shared publication- Anne Dallas
SomaGenics, Inc., Santa Cruz, California, USA
1 shared publication
Latest Publications
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 435-445
Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds
Objective: To evaluate the efficacy of layer-by-layer (LbL) formulated therapeutic RNAs that inhibit PHD2 and microRNA-210 (miR-210), to improve impaired diabetic wound healing. Approach: We employed the diabetic neuroischemic rabbit model of impaired wound healing. Diabetes was induced in the rabbits with alloxan, and neuroischemia was induced by ligating the central neurovascular bundle of each ear. Four 6-mm full-thickness wounds were creating on each ear. A layer-by-layer (LbL) technique was employed to conformally coat the wound dressings with a chemically modified antisense RNA (antimiR) against miR-210 and an sshRNA targeting PHD2. Results: Wound healing was improved by the antimiR-210 but not the PHD2-sshRNA. Specific knockdown of miR-210 in tissue as measured by RT-qPCR was approximately 8 Ct greater than nonspecific controls, and this apparent level of knockdown (>99%) suggests that delivery to the tissue is highly efficient at the administered dose. Innovation: Use of novel therapeutic RNAs and the LbL system to deliver them to the diabetic wound. Conclusion: Healing of ischemic/neuropathic wounds in diabetic rabbits was accelerated upon inhibition of miR-210 by LbL delivery to the wound bed of a chemically modified antisense RNA targeting this microRNA.
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 435-445
Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds
Objective: To evaluate the efficacy of layer-by-layer (LbL) formulated therapeutic RNAs that inhibit PHD2 and microRNA-210 (miR-210), to improve impaired diabetic wound healing. Approach: We employed the diabetic neuroischemic rabbit model of impaired wound healing. Diabetes was induced in the rabbits with alloxan, and neuroischemia was induced by ligating the central neurovascular bundle of each ear. Four 6-mm full-thickness wounds were creating on each ear. A layer-by-layer (LbL) technique was employed to conformally coat the wound dressings with a chemically modified antisense RNA (antimiR) against miR-210 and an sshRNA targeting PHD2. Results: Wound healing was improved by the antimiR-210 but not the PHD2-sshRNA. Specific knockdown of miR-210 in tissue as measured by RT-qPCR was approximately 8 Ct greater than nonspecific controls, and this apparent level of knockdown (>99%) suggests that delivery to the tissue is highly efficient at the administered dose. Innovation: Use of novel therapeutic RNAs and the LbL system to deliver them to the diabetic wound. Conclusion: Healing of ischemic/neuropathic wounds in diabetic rabbits was accelerated upon inhibition of miR-210 by LbL delivery to the wound bed of a chemically modified antisense RNA targeting this microRNA.
- Open Access
Correction: Chhalliyil et al. A Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant. Foods 2020, 9, 1245
The stated objective of the paper was to provide regulatory laboratories and industry laboratories a complete, legally robust method for the quantitative detection of SU canola
Open AccessCorrection: Chhalliyil et al. A Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant. Foods 2020, 9, 1245
The stated objective of the paper was to provide regulatory laboratories and industry laboratories a complete, legally robust method for the quantitative detection of SU canola
- Open Access
A Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant
Discussion regarding the regulatory status of genome-edited crops has focused on precision of editing and on doubts regarding the feasibility of analytical monitoring compliant with existing GMO regulations. Effective detection methods are important, both for regulatory enforcement and traceability in case of biosafety, environmental or socio-economic impacts. Here, we approach the analysis question for the first time in the laboratory and report the successful development of a quantitative PCR detection method for the first commercialized genome-edited crop, a canola with a single base pair edit conferring herbicide tolerance. The method is highly sensitive and specific (quantification limit, 0.05%), compatible with the standards of practice, equipment and expertise typical in GMO laboratories, and readily integrable into their analytical workflows, including use of the matrix approach. The method, validated by an independent laboratory, meets all legal requirements for GMO analytical methods in jurisdictions such as the EU, is consistent with ISO17025 accreditation standards and has been placed in the public domain. Having developed a qPCR method for the most challenging class of genome edits, single-nucleotide variants, this research suggests that qPCR-based method development may be applicable to virtually any genome-edited organism. This advance resolves doubts regarding the feasibility of extending the regulatory approach currently employed for recombinant DNA-based GMOs to genome-edited organisms.
Open AccessA Real-Time Quantitative PCR Method Specific for Detection and Quantification of the First Commercialized Genome-Edited Plant
Discussion regarding the regulatory status of genome-edited crops has focused on precision of editing and on doubts regarding the feasibility of analytical monitoring compliant with existing GMO regulations. Effective detection methods are important, both for regulatory enforcement and traceability in case of biosafety, environmental or socio-economic impacts. Here, we approach the analysis question for the first time in the laboratory and report the successful development of a quantitative PCR detection method for the first commercialized genome-edited crop, a canola with a single base pair edit conferring herbicide tolerance. The method is highly sensitive and specific (quantification limit, 0.05%), compatible with the standards of practice, equipment and expertise typical in GMO laboratories, and readily integrable into their analytical workflows, including use of the matrix approach. The method, validated by an independent laboratory, meets all legal requirements for GMO analytical methods in jurisdictions such as the EU, is consistent with ISO17025 accreditation standards and has been placed in the public domain. Having developed a qPCR method for the most challenging class of genome edits, single-nucleotide variants, this research suggests that qPCR-based method development may be applicable to virtually any genome-edited organism. This advance resolves doubts regarding the feasibility of extending the regulatory approach currently employed for recombinant DNA-based GMOs to genome-edited organisms.